TC BioPharm Beats the Odds and Keeps Its Nasdaq Listing

TC BioPharm, a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, is pleased to announce that it has successfully regained compliance with the Nasdaq Stock Market Listing Rule 5550(b). Thanks to this accomplishment, the Company’s American depositary shares will continue to be listed on the Nasdaq Global Select Market.

On January 19, 2019, Nasdaq’s listing qualifications staff wrote to the Company to inform them that the Company had not met the criteria for continued listing on The Nasdaq Capital Market due to a failure to reach a minimum Market Value of Listed Securities (MVLS) of $35,000,000 as specified in Nasdaq Listing Rule 5550(b). Failing to achieve the necessary MVLS puts the Company at risk of delisting.

On July 27, 2023, the Company received a letter from Nasdaq confirming that it had regained compliance with the shareholder equity concerns previously identified. Having accepted the Company’s plan to this effect, Nasdaq has mandated a Panel Monitor to oversee the Company’s compliance with its listing rules over the next year.

About TC BioPharm (Holdings) PLC

TC BioPharm is a leading clinical-stage biopharmaceutical company developing groundbreaking gamma-delta T cell therapies for the treatment of cancer. With demonstrated efficacy in acute myeloid leukemia, these naturally occurring immune cells bring the best of both innate and adaptive immune systems to target diseased tissue, eradicating solid and liquid tumors alike. TC BioPharm harnesses both unmodified and CAR modified gamma-delta T cells in an allogeneic approach to provide pioneering cancer treatments.

TC BioPharm is transforming the field of cancer treatment through the development of their groundbreaking gamma-delta T cell therapies. Having conducted multiple successful clinical trials, they are now conducting Phase 2b/3 pivotal trials using their proprietary allogeneic CryoTC technology and OmnImmune® to provide frozen product to clinics worldwide.

They also have a robust pipeline of future indications and a substantial IP/patent portfolio, as well as their own manufacturing facility to regulate cost and product quality. Through their work, TC BioPharm is setting a new standard in cancer treatment – one with the potential to save countless lives.

Leave a Comment